Experimental drug aims to tame rare liver disease
NCT ID NCT05104853
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new drug called CNP-104 in 42 adults with primary biliary cholangitis, a rare liver disease, who did not get better with standard treatments. The drug is designed to calm the immune system's attack on the bile ducts. The main goals were to check safety and see if it could lower liver damage markers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CNP-104 (a peptide-based immunotherapy)
What this could lead to
If successful, this could point toward a new treatment option for people with primary biliary cholangitis who do not respond to current medications.
What could go wrong
This is an early-phase trial with only 42 participants, so results may not apply to everyone. The treatment may not improve liver function or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic - Florida
Weston, Florida, 33331, United States
-
Digestive Healthcare of Georgia
Atlanta, Georgia, 30309, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Florida Research Institute
Lakewood Rch, Florida, 34211-4930, United States
-
GI PROS Research
Naples, Florida, 34102, United States
-
Henry Ford Health System
Novi, Michigan, 48377, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic Florida
Jacksonville, Florida, 32224, United States
-
Montefiore Medical Center
The Bronx, New York, 10467, United States
-
OM Research
Lancaster, California, 93534, United States
-
Peak Gastroenterology Associates
Colorado Springs, Colorado, 80907, United States
-
Southern California Research Center
Coronado, California, 92118, United States
-
Texas Liver Institute
San Antonio, Texas, 78215, United States
-
University of California Davis Health
Sacramento, California, 95817, United States
-
University of Chicago Medical Center
Chicago, Illinois, 60637, United States
-
University of Florida - Hepatology Research
Gainesville, Florida, 32610, United States
-
University of Virginia
Charlottesville, Virginia, 22903, United States
-
Washington University School of Medicine in St. Louis
St Louis, Missouri, 63110, United States
-
Yale School of Medicine
New Haven, Connecticut, 06520, United States